MX2023008803A - Inmunoconjugados que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos. - Google Patents

Inmunoconjugados que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos.

Info

Publication number
MX2023008803A
MX2023008803A MX2023008803A MX2023008803A MX2023008803A MX 2023008803 A MX2023008803 A MX 2023008803A MX 2023008803 A MX2023008803 A MX 2023008803A MX 2023008803 A MX2023008803 A MX 2023008803A MX 2023008803 A MX2023008803 A MX 2023008803A
Authority
MX
Mexico
Prior art keywords
immunoconjugates
antigen binding
binding domains
related peptidase
kallikrein related
Prior art date
Application number
MX2023008803A
Other languages
English (en)
Inventor
Shalom Goldberg
Sathyadevi Venkataramani
Theresa Mcdevitt
Kristen Wiley
Fei Shen
Ryan M Smith
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023008803A publication Critical patent/MX2023008803A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

En la presente descripción se proporcionan inmunoconjugados, tales como radioinmunoconjugados, que comprenden una entidad terapéutica conjugado con un anticuerpo o dominio de unión al antígeno con especificidad de unión para hK2. En ciertas modalidades, el inmunoconjugado específico de hK2 demuestra una vida media corta. También se proporcionan en la presente descripción métodos para usar los inmunoconjugados para dirigirse selectivamente a células cancerosas y para tratar enfermedades tales como cáncer de próstata.
MX2023008803A 2021-01-27 2022-01-26 Inmunoconjugados que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos. MX2023008803A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142147P 2021-01-27 2021-01-27
US202163144586P 2021-02-02 2021-02-02
PCT/IB2022/050673 WO2022162549A2 (en) 2021-01-27 2022-01-26 Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses

Publications (1)

Publication Number Publication Date
MX2023008803A true MX2023008803A (es) 2023-08-04

Family

ID=80447388

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008803A MX2023008803A (es) 2021-01-27 2022-01-26 Inmunoconjugados que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos.

Country Status (8)

Country Link
EP (1) EP4284446A2 (es)
JP (1) JP2024503924A (es)
KR (1) KR20230142482A (es)
AU (1) AU2022213825A1 (es)
CA (1) CA3205707A1 (es)
IL (1) IL304656A (es)
MX (1) MX2023008803A (es)
WO (1) WO2022162549A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022001368A2 (pt) 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
CA3240194A1 (en) * 2021-11-09 2023-05-19 Edward Cleator Macrocyclic compounds and methods of making the same
CN118613288A (zh) * 2022-01-26 2024-09-06 詹森生物科技公司 包含激肽释放酶相关肽酶2抗原结合结构域的免疫缀合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
CA3006800C (en) 2010-03-31 2022-10-04 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
LT2931030T (lt) 2012-12-14 2020-11-10 Open Monoclonal Technology, Inc. Polinukleotidai, koduojantys graužikų antikūnus su žmogaus idiotipais, ir juos apimantys gyvūnai
HUE043875T2 (hu) 2013-11-19 2019-09-30 Fredax Ab Humanizált, kallikrein-2 elleni antitest
US20180326102A1 (en) 2015-11-18 2018-11-15 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
US11554182B2 (en) 2017-03-30 2023-01-17 Cornell University Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
CN113056288A (zh) 2018-11-20 2021-06-29 康奈尔大学 放射性核素的大环配合物及其在癌症的放射治疗中的应用
MX2021013667A (es) 2019-05-10 2022-01-31 Janssen Biotech Inc Quelantes macrocíclicos y métodos de uso de estos.
BR112022001368A2 (pt) * 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
WO2021060350A1 (ja) 2019-09-27 2021-04-01 株式会社Ｊ－オイルミルズ 食肉加工品の製造方法

Also Published As

Publication number Publication date
KR20230142482A (ko) 2023-10-11
EP4284446A2 (en) 2023-12-06
IL304656A (en) 2023-09-01
WO2022162549A2 (en) 2022-08-04
WO2022162549A3 (en) 2022-09-29
JP2024503924A (ja) 2024-01-29
AU2022213825A1 (en) 2023-09-14
CA3205707A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
MX2023008803A (es) Inmunoconjugados que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos.
PH12020550741A1 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
MX2023013118A (es) Derivados del exatecan y sus conjugados anticuerpo-farmaco.
MX2021014094A (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso.
NZ595574A (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
PE20170517A1 (es) Conjugados de anticuerpo-farmaco-anti-ptk7
DK1594542T3 (da) Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
NZ599045A (en) New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
NZ596490A (en) Monoclonal antibodies that bind GT468 for the treatment of cancer
WO2002100326A3 (en) Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
NZ587132A (en) Anti-cd79b antibodies and immunoconjugates and methods of use
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
WO2006099141A3 (en) Anti-mesothelin antibodies
MA31662B1 (fr) Anticorps chimeres et humanises anti-cd44 influencant la cytotoxicite des cellules cancereuses
MX2021009138A (es) Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco.
MX2022010599A (es) Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos.
MX2021010003A (es) Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
GEP20135826B (en) Novel antibodies used to treat cancer
MX2023009761A (es) Inmunoconjugados para terapia dirigida con radioisotopos.
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
FR3096259B1 (fr) conjugués anticorps-médicament et leur utilisation en thérapie
MX2023014282A (es) Conjugados de neodegradador-anticuerpo anti-cumulo de diferenciación 33 (cd33).